Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Dosing With Eltrombopag in Refractory Severe Aplastic Anemia
NCT01891994Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Participants With Drug Response as Defined by Clinically-signficant Hematologic Improvements at 24 weeks. Started Jun 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT01891994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01891994.